智通财经APP获悉，康宁杰瑞制药-B(09966)涨超5%，截至发稿，涨5.87%，报7.4港元，成交额2252.21万港元。
消息面上，康宁杰瑞生物制药日前宣布，HER2双特异性抗体偶联药物（ADC）JSKN003获得国家药品监督管理局（NMPA）药品审评中心（CDE）突破性疗法认定，用于治疗铂耐药复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌，且不限HER2表达水平。此次获得突破性疗法认定，有望加快JSKN003的临床开发和审评审批速度。
此外，康宁杰瑞制药将于3月25日（下周二）发布2024年度业绩。该公司此前发布盈喜，预期将于截至2024年12 月31日止年度取得利润不少于人民币1.5亿元，而截至2023年12月31日止年度则取得亏损约人民币2.106亿元，为公司首次实现年度盈利。公告称，公司于报告期内转亏为盈，主要基于三项授权合作和销售收入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.